by Johannes Angerer, Medical University of Vienna New results from researchers at MedUni Vienna’s Center for Pathobiochemistry and Genetics show that a protein called mTORC2, which is the target of newly developed cancer drugs, is not even active in colorectal cancer. mTORC2 activity was only found in certain immune cells, which actually need this protein...
Tag: <span>mTOR protein</span>
Post
Commonly used anti-rejection drug could be repurposed to treat some liver cancers
Research from the University of Pittsburgh School of Medicine in animal models and patient tissues has identified a new molecular pathway in the liver that suggests a commonly used anti-rejection medication could be repurposed to treat certain liver cancers. Mouse liver tissues showing cells surrounding the central vein with active mTOR (red) and glutamine synthetase...